Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes. A panel discussion with audience participation.
Chesebro
J H
JH
The Cardiovascular Institute, Mount Sinai Hospital, New York, New York 10029, USA.
Verheugt
F W
FW
Kontny
F
F
Fry
E T
ET
Wallentin
L
L
Camm
A J
AJ
Bechtold
H
H
D000789:Angina, Unstable / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications; D017985:Dalteparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D015912:Thrombolytic Therapy
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D017985:Dalteparin